FAPI Newsletter Q1 – 2026
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
Dear FAPI […]
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
Dear FAPI […]
Magdalena Staniszewska, Ralph Hübner, Camilla Locatelli, Douglas Howard, Matilde Forni, Francis Man, Bent Wilhelm Schoultz, […]
Helena Lanzafame, Ilektra A. Mavroeidi, Kim M. Pabst, Pedro Fragoso Costa, Martin Schuler, Sebastian Bauer, […]
Emil Novruzov, Eduards Mamlins, Liam Widjaja, Sophie C Siegmund, Tadashi Watabe, Yuriko Mori, Christian Stief, […]
Presented by: Sherly Mosessian, PhD, Chief Scientific Officer, SOFIE
8th Theranostics World Congress; Cape Town, South […]
Seven SOFIE radiopharmacies now produce the FAP-targeting radiopharmaceutical, as SOFIE launches Phase 3 clinical trials […]
Results from SOFIE’s Phase 2 diagnostic study on [18F]FAPI-74 PET were presented to the oncological […]
FAPI-PRO is a GO!
SOFIE is proud to announce FAPI-PRO, our [18F]FAPI-74 Phase 3 study on […]